Skip to content

Ocular Therapeutix

US · OCUL #2978 by market cap Listed 1970
5.57 -0.29 -4.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.7 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
95.35% +0.65pp
Institutions
308 -4
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund51.19%
Hedge Fund19.13%
VC/PE Fund15.02%
Family Office/Trust5.73%
Public Company2.04%
Private Company1.36%
Individual/Insider1.24%
Insurance Company0.60%
Government Pension Fund0.26%
Other3.41%

Top holders as of 2026-09-30

FMR 15.07% · 33.16M sh
BlackRock 9.08% · 19.97M sh
Deep Track Capital, LP 8.95% · 19.69M sh
Avoro Capital Advisors LLC 5.70% · 12.54M sh
Summer Road LLC 5.66% · 12.46M sh
VR Management, LLC 4.70% · 10.35M sh
Vanguard Capital Management, LLC 4.06% · 8.94M sh
T. Rowe Price Group, Inc. 3.46% · 7.62M sh
State Street Global Advisors 2.53% · 5.58M sh
Logos Global Management, L.P. 2.41% · 5.30M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 21 buys · 29 sells

NameRoleStake
Pravin Dugel Chairperson & CEO 0.36%
Antony Mattessich Former Chief Executive Officer 0.18%
Richard Lindstrom Independent Director 0.11%
Donald Notman Chief Operating Officer (Leave of Absence) 0.08%
Jeffrey Heier Chief Scientific Officer 0.08%
Sanjay Nayak Former Chief Strategy Officer 0.08%
Peter Kaiser Chief Development Officer 0.06%
Nadia Waheed Chief Medical Officer 0.04%
William Link -- 0.04%
Steve Meyers Chief Commercial Officer 0.03%
Namrata Saroj Chief Business Officer 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-05 Riad Sherif Director Other Acquisition +28,000 --
2026-11-05 Riad Sherif Director Other Derivative Acquisition +88,000 $6.60
2026-11-04 Namrata Saroj Chief Business Officer Open Market Disposition -35,370 $6.55
2026-10-07 Todd Anderman Chief Legal Officer Open Market Disposition -11,984 $7.29
2026-10-01 Jeffrey Heier Chief Scientific Officer Open Market Disposition -10,869 $7.05
2026-10-01 Jeffrey Heier Independent Director Intent to Sell (Form 144) -10,869 $7.05
2026-10-01 Peter Kaiser Chief Development Officer Open Market Disposition -9,990 $7.05
2026-08-30 Donald Notman Chief Operating Officer (Leave of Absence) Open Market Disposition -1,099 $10.24
2026-08-24 Pravin Dugel Chairperson & CEO Other Acquisition +50,092 --
2026-08-24 Pravin Dugel Chairperson & CEO Other Disposition -50,092 --
2026-08-23 Jeffrey Heier Chief Scientific Officer Open Market Disposition -3,296 $10.78
2026-08-23 Peter Kaiser Chief Development Officer Open Market Disposition -3,035 $10.77
2026-08-23 Pravin Dugel Chairperson & CEO Open Market Disposition -21,649 $10.77
2026-08-23 Sanjay Nayak Former Chief Strategy Officer Open Market Disposition -1,897 $10.78
2026-06-15 Pravin Dugel Chairperson & CEO Other Acquisition +50,092 --
2026-06-15 Pravin Dugel Chairperson & CEO Other Disposition -50,092 --
2026-06-09 William Link -- Other Acquisition +14,000 --
2026-06-09 William Link -- Other Derivative Acquisition +44,000 $8.74
2026-06-09 Merilee Raines Independent Director Other Acquisition +14,000 --
2026-06-09 Merilee Raines Independent Director Other Derivative Acquisition +44,000 $8.74

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Ocular Therapeutix discussion 0 comments

Add a comment